María Agudelo

757 total citations
25 papers, 575 citations indexed

About

María Agudelo is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Infectious Diseases. According to data from OpenAlex, María Agudelo has authored 25 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 8 papers in Pediatrics, Perinatology and Child Health and 7 papers in Infectious Diseases. Recurrent topics in María Agudelo's work include Antibiotics Pharmacokinetics and Efficacy (16 papers), Pharmaceutical studies and practices (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). María Agudelo is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (16 papers), Pharmaceutical studies and practices (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). María Agudelo collaborates with scholars based in Colombia, United Kingdom and United States. María Agudelo's co-authors include Ómar Vesga, Carlos A. Rodríguez, Andrés F. Zuluaga, Carlos Peláez, Juan Carlos Cataño, Andrea Restrepo, Javier González, María Patricia Arbeláez, Gloria Inés Sánchez and Nelson Enrique Arias-Ortiz and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Vaccine.

In The Last Decade

María Agudelo

23 papers receiving 551 citations

Peers

Countries citing papers authored by María Agudelo

Since Specialization

Citations

This map shows the geographic impact of María Agudelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Agudelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Agudelo more than expected).

Fields of papers citing papers by María Agudelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Agudelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Agudelo. The network helps show where María Agudelo may publish in the future.

Co-authorship network of co-authors of María Agudelo

This figure shows the co-authorship network connecting the top 25 collaborators of María Agudelo. A scholar is included among the top collaborators of María Agudelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Agudelo. María Agudelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Understanding the decline in HPV vaccination in Colombia: A population-based analysis of girls and parents in early rollout cohorts 2025 ·Vaccine ·(unknown), María Agudelo, (unknown), Caroline Reuter, Nelson Enrique Arias-Ortiz, (unknown), (unknown), (unknown), Isabel Palacio, María Patricia Arbeláez, (unknown), (unknown), Karly S. Louie, Simon Beddows, Gloria Inés Sánchez	0
2	Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin 2019 ·PLoS ONE ·María Agudelo, Carlos A. Rodríguez, Andrés F. Zuluaga, Ómar Vesga	3
3	OBTENCIÓN DE UN MODELO MÚRIDO DE DIABETES INDUCIDA POR ESTREPTOZOTOCINA ÚTIL EN LA EVALUACIÓN FARMACODINÁMICA DE LA INSULINA REGULAR 2017 ·Revista Vitae ·(unknown), (unknown), (unknown), Carlos A. Rodríguez, (unknown), María Agudelo, Ómar Vesga	1
4	Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam 2016 ·PLoS ONE ·Carlos A. Rodríguez, María Agudelo, (unknown), Andrés F. Zuluaga, Ómar Vesga	9
5	In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products 2016 ·International Journal of Antimicrobial Agents ·Carlos A. Rodríguez, María Agudelo, Andrés F. Zuluaga, Ómar Vesga	18
6	Antifungal pharmacodynamics: Latin America's perspective 2016 ·The Brazilian Journal of Infectious Diseases ·Javier González, Carlos A. Rodríguez, María Agudelo, Andrés F. Zuluaga, Ómar Vesga	8
7	Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis 2015 ·PLoS ONE ·Javier González, Carlos A. Rodríguez, Andrés F. Zuluaga, María Agudelo, Ómar Vesga	2
8	Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model 2015 ·BMC Research Notes ·Andrés F. Zuluaga, Carlos A. Rodríguez, María Agudelo, Ómar Vesga	2
9	A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic mice 2015 ·Journal of Biomedical Science ·Andrés F. Zuluaga, (unknown), María Agudelo, Carlos A. Rodríguez, Ómar Vesga	3
10	Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam 2014 ·International Journal of Antimicrobial Agents ·María Agudelo, Carlos A. Rodríguez, Andrés F. Zuluaga, Ómar Vesga	9
11	An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics 2014 ·Antimicrobial Agents and Chemotherapy ·Carlos A. Rodríguez, María Agudelo, Javier González, Ómar Vesga, Andrés F. Zuluaga	10
12	Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator 2010 ·Antimicrobial Agents and Chemotherapy ·Ómar Vesga, María Agudelo, (unknown), Carlos A. Rodríguez, Andrés F. Zuluaga	67
13	In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin 2010 ·BMC Infectious Diseases ·Carlos A. Rodríguez, María Agudelo, Andrés F. Zuluaga, Ómar Vesga	34
14	Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model 2010 ·PLoS ONE ·Andrés F. Zuluaga, María Agudelo, (unknown), Carlos A. Rodríguez, Ómar Vesga	34
15	Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics 2009 ·PubMed ·Andrés F. Zuluaga, María Agudelo, Carlos A. Rodríguez, Ómar Vesga	86
16	Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia 2009 ·Journal of Infection ·Carlos A. Rodríguez, María Agudelo, Juan Carlos Cataño, Andrés F. Zuluaga, Ómar Vesga	24
17	Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases 2006 ·BMC Infectious Diseases ·Andrés F. Zuluaga, (unknown), Carlos A. Rodríguez, (unknown), María Agudelo, Ómar Vesga	152
18	Optimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae 2005 ·BMC Microbiology ·Andrea Restrepo, (unknown), María Agudelo, Carlos A. Rodríguez, Andrés F. Zuluaga, Ómar Vesga	23
19	FOUNDATION OF A FUNCTIONAL MURINE PATHOGEN FREE ANIMAL FACILITY IN COLOMBIA 2003 ·IATREIA ·Andrés F. Zuluaga, (unknown), (unknown), (unknown), María Agudelo, Ómar Vesga	1
20	Fundación del primer bioterio MPF funcional de Colombia 2003 ·IATREIA ·(unknown), (unknown), (unknown), (unknown), María Agudelo, Ómar Vesga	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact